导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.42% | 2310/4773 |
| 近一周 | -3.73% | 4514/5462 |
| 近一月 | -10.73% | 5186/5421 |
| 近一季 | -21.11% | 5002/5209 |
| 近半年 | -2.37% | 1877/4920 |
| 近一年 | 5.08% | 1635/4366 |
| 近两年 | 114.39% | 442/2954 |
| 近三年 | 74.15% | 261/2253 |
| 成立以来 | 134.81% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.37% 2261/4961 |
36.21% 900/5312 |
- - |
- - |
| 2025 | 54.26% 360/4813 |
-3.51% 3057/3635 |
3.87% 930/4076 |
54.97% 197/4524 |
-0.67% 2590/4813 |
| 2024 | 20.08% 490/3463 |
-1.66% 1258/2808 |
-6.16% 1869/3014 |
30.55% 132/3129 |
-0.33% 1386/3463 |
| 2023 | -22.18% 1923/2656 |
-0.71% 1819/2280 |
-7.68% 1885/2385 |
-10.00% 1930/2515 |
-5.68% 1454/2655 |
| 2022 | -28.44% 1559/2207 |
-19.57% 1475/1919 |
6.48% 692/2016 |
-18.85% 1739/2113 |
2.97% 795/2208 |
| 2021 | 15.70% 299/1822 |
-5.84% 960/1255 |
29.94% 45/1330 |
-6.51% 943/1466 |
1.15% 996/1822 |
| 2020 | 85.00% 34/1250 |
5.64% 52/1028 |
33.72% 27/1067 |
9.39% 651/1164 |
19.71% 70/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 交银创业板50指数C VS. 长安沪深300非周期A(740101) |